Research ExplorerPublicationsUsing PSMA imaging for prognostication in localized and adva...

Using PSMA imaging for prognostication in localized and advanced prostate cancer

Standard

Using PSMA imaging for prognostication in localized and advanced prostate cancer. / Roberts, Matthew J; Maurer, Tobias; Perera, Marlon; Eiber, Matthias; Hope, Thomas A; Ost, Piet; Siva, Shankar; Hofman, Michael S; Murphy, Declan G; Emmett, Louise; Fendler, Wolfgang P.

In: NAT REV UROL, Vol. 20, No. 1, 01.2023, p. 23-47.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Roberts, MJ, Maurer, T, Perera, M, Eiber, M, Hope, TA, Ost, P, Siva, S, Hofman, MS, Murphy, DG, Emmett, L & Fendler, WP 2023, 'Using PSMA imaging for prognostication in localized and advanced prostate cancer', NAT REV UROL, vol. 20, no. 1, pp. 23-47. https://doi.org/10.1038/s41585-022-00670-6

APA

Roberts, M. J., Maurer, T., Perera, M., Eiber, M., Hope, T. A., Ost, P., Siva, S., Hofman, M. S., Murphy, D. G., Emmett, L., & Fendler, W. P. (2023). Using PSMA imaging for prognostication in localized and advanced prostate cancer. NAT REV UROL, 20(1), 23-47. https://doi.org/10.1038/s41585-022-00670-6

Vancouver

Roberts MJ, Maurer T, Perera M, Eiber M, Hope TA, Ost P et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. NAT REV UROL. 2023 Jan;20(1):23-47. https://doi.org/10.1038/s41585-022-00670-6

Bibtex

@article{58f997155d1748b6bb875699684f0b4c,
title = "Using PSMA imaging for prognostication in localized and advanced prostate cancer",
abstract = "The use of prostate-specific membrane antigen (PSMA)-directed applications in modern prostate cancer management has evolved rapidly over the past few years, helping to establish new treatment pathways and provide further insights into prostate cancer biology. However, the prognostic implications of PSMA-PET have not been studied systematically, owing to rapid clinical implementation without long follow-up periods to determine intermediate-term and long-term oncological outcomes. Currently available data suggest that traditional prognostic factors and survival outcomes are associated with high PSMA expression (both according to immunohistochemistry and PET uptake) in men with localized and biochemically recurrent disease. Treatment with curative intent (primary and/or salvage) often fails when PSMA-positive metastases are present; however, the sensitivity of PSMA-PET in detecting all metastases is poor. Low PSMA-PET uptake in recurrent disease is a favourable prognostic factor; however, it can be associated with poor prognosis in conjunction with high 18F-fluorodeoxyglucose uptake in metastatic castration-resistant prostate cancer. Clinical trials embedding PSMA-PET for guiding management with reliable oncological outcomes are needed to support ongoing clinical use.",
keywords = "Humans, Male, Positron Emission Tomography Computed Tomography/methods, Positron-Emission Tomography/methods, Prognosis, Prostate/diagnostic imaging, Prostatic Neoplasms/diagnostic imaging",
author = "Roberts, {Matthew J} and Tobias Maurer and Marlon Perera and Matthias Eiber and Hope, {Thomas A} and Piet Ost and Shankar Siva and Hofman, {Michael S} and Murphy, {Declan G} and Louise Emmett and Fendler, {Wolfgang P}",
note = "{\textcopyright} 2022. Springer Nature Limited.",
year = "2023",
month = jan,
doi = "10.1038/s41585-022-00670-6",
language = "English",
volume = "20",
pages = "23--47",
journal = "NAT REV UROL",
issn = "1759-4812",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Using PSMA imaging for prognostication in localized and advanced prostate cancer

AU - Roberts, Matthew J

AU - Maurer, Tobias

AU - Perera, Marlon

AU - Eiber, Matthias

AU - Hope, Thomas A

AU - Ost, Piet

AU - Siva, Shankar

AU - Hofman, Michael S

AU - Murphy, Declan G

AU - Emmett, Louise

AU - Fendler, Wolfgang P

N1 - © 2022. Springer Nature Limited.

PY - 2023/1

Y1 - 2023/1

N2 - The use of prostate-specific membrane antigen (PSMA)-directed applications in modern prostate cancer management has evolved rapidly over the past few years, helping to establish new treatment pathways and provide further insights into prostate cancer biology. However, the prognostic implications of PSMA-PET have not been studied systematically, owing to rapid clinical implementation without long follow-up periods to determine intermediate-term and long-term oncological outcomes. Currently available data suggest that traditional prognostic factors and survival outcomes are associated with high PSMA expression (both according to immunohistochemistry and PET uptake) in men with localized and biochemically recurrent disease. Treatment with curative intent (primary and/or salvage) often fails when PSMA-positive metastases are present; however, the sensitivity of PSMA-PET in detecting all metastases is poor. Low PSMA-PET uptake in recurrent disease is a favourable prognostic factor; however, it can be associated with poor prognosis in conjunction with high 18F-fluorodeoxyglucose uptake in metastatic castration-resistant prostate cancer. Clinical trials embedding PSMA-PET for guiding management with reliable oncological outcomes are needed to support ongoing clinical use.

AB - The use of prostate-specific membrane antigen (PSMA)-directed applications in modern prostate cancer management has evolved rapidly over the past few years, helping to establish new treatment pathways and provide further insights into prostate cancer biology. However, the prognostic implications of PSMA-PET have not been studied systematically, owing to rapid clinical implementation without long follow-up periods to determine intermediate-term and long-term oncological outcomes. Currently available data suggest that traditional prognostic factors and survival outcomes are associated with high PSMA expression (both according to immunohistochemistry and PET uptake) in men with localized and biochemically recurrent disease. Treatment with curative intent (primary and/or salvage) often fails when PSMA-positive metastases are present; however, the sensitivity of PSMA-PET in detecting all metastases is poor. Low PSMA-PET uptake in recurrent disease is a favourable prognostic factor; however, it can be associated with poor prognosis in conjunction with high 18F-fluorodeoxyglucose uptake in metastatic castration-resistant prostate cancer. Clinical trials embedding PSMA-PET for guiding management with reliable oncological outcomes are needed to support ongoing clinical use.

KW - Humans

KW - Male

KW - Positron Emission Tomography Computed Tomography/methods

KW - Positron-Emission Tomography/methods

KW - Prognosis

KW - Prostate/diagnostic imaging

KW - Prostatic Neoplasms/diagnostic imaging

U2 - 10.1038/s41585-022-00670-6

DO - 10.1038/s41585-022-00670-6

M3 - SCORING: Review article

C2 - 36473945

VL - 20

SP - 23

EP - 47

JO - NAT REV UROL

JF - NAT REV UROL

SN - 1759-4812

IS - 1

ER -